A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors Harboring Selected Mutations In Kras
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Pathologically documented, locally advanced or metastatic malignancy with any RAS (KRAS, NRAS, HRAS) mutations identified through deoxyribonucleic acid (DNA) sequencing or polymerase chain reaction (PCR) test of an archival biopsy or circulating tumor DNA (ctDNA) obtained within 3 years of C1D1 or fresh tumor biopsy
    2. Subject must have received prior standard therapy appropriate for tumor type and stage
    3. Subjects must provide archival tumor samples collected within 3 years of C1D1 or be willing to undergo pretreatment tumor biopsy

You may not be eligible for this study if the following are true:

    1. Subject with tumors harboring KRASG12C mutations are not eligible
    2. Subjects with primary central nervous system (CNS) brain tumors
    3. Subject has known or suspected leptomeningeal or brain metastases or spinal cord compression



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.